BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 31703741)

  • 21. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.
    Molfenter T; Knudsen HK; Brown R; Jacobson N; Horst J; Van Etten M; Kim JS; Haram E; Collier E; Starr S; Toy A; Madden L
    Implement Sci; 2017 Nov; 12(1):135. PubMed ID: 29141653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful engagement in buprenorphine treatment among hospitalized patients with opioid use disorder and trauma.
    Bhatraju EP; Ludwig-Barron N; Takagi-Stewart J; Sandhu HK; Klein JW; Tsui JI
    Drug Alcohol Depend; 2020 Oct; 215():108253. PubMed ID: 32890919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The case for a medication first approach to the treatment of opioid use disorder.
    Winograd RP; Presnall N; Stringfellow E; Wood C; Horn P; Duello A; Green L; Rudder T
    Am J Drug Alcohol Abuse; 2019; 45(4):333-340. PubMed ID: 31084515
    [No Abstract]   [Full Text] [Related]  

  • 24. Diagnosis and Management of Opioid Use Disorder in Hospitalized Patients.
    Herscher M; Fine M; Navalurkar R; Hirt L; Wang L
    Med Clin North Am; 2020 Jul; 104(4):695-708. PubMed ID: 32505261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of a Multimodal Educational Intervention for Primary Care Physicians With Prescriptions of Buprenorphine for Opioid Use Disorders.
    Clark B; Kai M; Dix R; White J; Rozenfeld Y; Levy S; Engstrom K
    JAMA Netw Open; 2019 Oct; 2(10):e1913818. PubMed ID: 31642929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unintended consequences of methadone regulation for opioid use disorder treatment among hospitalized patients.
    Calcaterra SL; Dafoe A; Tietbohl C; Thurman L; Bredenberg E
    J Hosp Med; 2024 Jun; 19(6):460-467. PubMed ID: 38507276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices.
    Andraka-Christou B; Capone MJ
    Int J Drug Policy; 2018 Apr; 54():9-17. PubMed ID: 29324253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention.
    D'Onofrio G; Chawarski MC; O'Connor PG; Pantalon MV; Busch SH; Owens PH; Hawk K; Bernstein SL; Fiellin DA
    J Gen Intern Med; 2017 Jun; 32(6):660-666. PubMed ID: 28194688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
    Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
    Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
    [No Abstract]   [Full Text] [Related]  

  • 30. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bridging Recovery Initiative Despite Gaps in Entry (BRIDGE): study protocol for a randomized controlled trial of a bridge clinic compared with usual care for patients with opioid use disorder.
    Marcovitz DE; White KD; Sullivan W; Limper HM; Dear ML; Buie R; Edwards DA; Chastain C; Kast KA; Lindsell CJ;
    Trials; 2021 Oct; 22(1):757. PubMed ID: 34717736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A qualitative assessment of emergency physicians' experiences with robust emergency department buprenorphine bridge programs.
    Heil JM; Lassiter JM; Salzman MS; Herring A; Hoppe J; Lynch M; Weiner SG; Roberts B; Haroz R
    Acad Emerg Med; 2024 Jun; 31(6):576-583. PubMed ID: 38357749
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Substance use disorder approaches in US primary care clinics with national reputations as workforce innovators.
    O'Malley DM; Abraham CM; Lee HS; Rubinstein EB; Howard J; Hudson SV; Kieber-Emmons AM; Crabtree BF
    Fam Pract; 2022 Mar; 39(2):282-291. PubMed ID: 34423366
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of access to addiction specialist on attitudes, beliefs and hospital-based opioid use disorder related care: A survey of hospitalist physicians.
    Calcaterra SL; Binswanger IA; Edelman EJ; McNair BK; Wakeman SE; O'Connor PG
    Subst Abus; 2022; 43(1):143-151. PubMed ID: 32267807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rates of substance use disorder treatment seeking visits after emergency department-initiated buprenorphine.
    Jennings LK; Bogan C; McCauley JJ; Moreland A; Lane S; Ward R; Hartwell KJ; Haynes L; Brady KT
    Am J Emerg Med; 2020 May; 38(5):975-978. PubMed ID: 32081555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A qualitative examination of the current management of opioid use disorder and barriers to prescribing buprenorphine in a Canadian emergency department.
    Wiercigroch D; Hoyeck P; Sheikh H; Hulme J
    BMC Emerg Med; 2021 Apr; 21(1):48. PubMed ID: 33858328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of an opioid use disorder consult service on hospitalized trauma patients with opioid use disorder.
    Muller M; Weyer G; Zakrison T; Ari M
    J Trauma Acute Care Surg; 2023 Aug; 95(2):226-233. PubMed ID: 36914601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders.
    Reif S; Brolin MF; Stewart MT; Fuchs TJ; Speaker E; Mazel SB
    J Subst Abuse Treat; 2020 Jan; 108():33-39. PubMed ID: 31358328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. COVID-19: A catalyst for change in telehealth service delivery for opioid use disorder management.
    Mehtani NJ; Ristau JT; Snyder H; Surlyn C; Eveland J; Smith-Bernardin S; Knight KR
    Subst Abus; 2021; 42(2):205-212. PubMed ID: 33684331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.
    Socias ME; Ahamad K; Le Foll B; Lim R; Bruneau J; Fischer B; Wild TC; Wood E; Jutras-Aswad D
    Contemp Clin Trials; 2018 Jun; 69():21-27. PubMed ID: 29627621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.